Avoid common mistakes on your manuscript.
Correction to: European Journal of Clinical Pharmacology
The original publication of this paper contains two errors. We apologize for any inconvenience this may have caused.
1. The Median (Q25–Q75) of dose-adjusted C0 of tacrolimus for the two genotypes of CYP3A4*1G, CYP3A4 rs4646437 and CYP3A7 rs10211 in Table 2 should be exchanged. The corrected table 2 is as followed:
SNP | Number | Genotype | Median (Q25–Q75) | p |
---|---|---|---|---|
CYP3A5*3 | 39 | A | 54.2(42.3 – 80.0) | 0.00006* |
31 | NA | 90.7(65.7 – 171.5) | ||
CYP3A4*1G | 30 | T | 59.6(42.8 – 83.1) | 0.011 |
38 | NT | 82.6(58.5 – 169.7) | ||
CYP3A4 rs4646437 | 11 | T | 51.7 (32.1 – 91.0) | 0.011 |
56 | NT | 73.6(54.5 – 133.7) | ||
CYP3A7 rs2257401 | 39 | C | 62.4(42.6 – 84.9) | 0.001* |
26 | NC | 90.7(62.7 – 192.6) | ||
CYP3A7 rs10211 | 34 | G | 59.6(42.4 – 80.2) | 0.0004* |
31 | NG | 101.8(64.2 – 187.3) |
2. The data “94%” in “the tacrolimus concentration in patients without CYP3A5*3 A allele was 94% higher than those with A allele (90.7 vs 54.2, P = 0.00006).” of the abstract should be “67%”.
Author information
Authors and Affiliations
Corresponding authors
Additional information
The online version of the original article can be found at https://doi.org/10.1007/s00228-019-02726-w
Rights and permissions
About this article
Cite this article
Liu, H., Xu, Q., Huang, W. et al. Correction to: CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic syndrome. Eur J Clin Pharmacol 77, 1251–1252 (2021). https://doi.org/10.1007/s00228-020-02875-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-020-02875-3